Fig. 3: Subject survival after start of BAY1436032 treatment.
From: Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results
Overall survival is depicted according to dosing cohort (a) and for all 27 treated subjects (b). Censored subjects are indicated with an asterisk.
